

JOHNSON & JOHNSON

Reported by
WOLK JOSEPH J

FORM 3

(Initial Statement of Beneficial Ownership)

Filed 07/11/18 for the Period Ending 07/02/18

Address	ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ, 08933
Telephone	732-524-2455
CIK	0000200406
Symbol	JNJ
SIC Code	2834 - Pharmaceutical Preparations
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	01/01

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
Wolk Joseph J			7/2/2018		JOHNSON & JOHNSON [JNJ]		
(Last) (First) (Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
ONE JOHNSON & JOHNSON PLAZA			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Exec VP, CFO /				
(Street)			5. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)		
NEW BRUNSWICK, NJ 08933					<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)							

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9576.4650	D	
Common Stock	1775.0000 (1)	I	By 401k

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Options (Right to Buy) (2)	1/17/2016	1/13/2023	Common Stock	1855.0000	\$72.5400	D	
Employee Stock Options (Right to Buy) (2)	2/11/2017	2/9/2024	Common Stock	12926.0000	\$90.4400	D	
Employee Stock Options (Right to Buy) (2)	2/10/2018	2/9/2025	Common Stock	13015.0000	\$100.0600	D	
Employee Stock Options (Right to Buy) (2)	2/9/2019	2/8/2026	Common Stock	16820.0000	\$101.8700	D	
Employee Stock Options (Right to Buy) (2)	2/13/2020	2/13/2027	Common Stock	19241.0000	\$115.6700	D	
Employee Stock Options (Right to Buy) (2)	2/12/2021	2/11/2028	Common Stock	12066.0000	\$129.5100	D	
Restricted Share Units (3)	2/8/2019	(3)	Common Stock	2540.0000	(3)	D	
Restricted Share Units (3)	2/12/2021	(3)	Common Stock	2543.0000	(3)	D	

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Restricted Share Units (3)	2/13/2020	(3)	Common Stock	3400.0000	(3)	D	

Explanation of Responses:

- (1) Shares held in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (6/30/2018).
- (2) Vested and exercisable one day after the third anniversary of the date of the grant.
- (3) Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock and vests on the third anniversary of the date of grant.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wolk Joseph J ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933			Exec VP, CFO	

Signatures

Linda E. King, as attorney-in-fact for Joseph J. Wolk

7/11/2018

—Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.